Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3319512 | 0.80 | HSD11B1 (0.50) | HSD11B1ALDH1A1NPSR1TSHRHPGD | |
| SCHEMBL1770088 | 0.73 | HSD11B1 (1.00) | HSD11B1ALDH1A1CYP3A4KDM4ELMNA | |
| SCHEMBL3321222 | 0.72 | HSD11B1 (0.53) | HSD11B1ALDH1A1NPSR1HPGDLMNA | |
| SCHEMBL1770092 | 0.71 | HSD11B1 (0.52) | HSD11B1ALDH1A1KDM4E | |
| SCHEMBL1770472 | 0.71 | HSD11B1 (0.56) | HSD11B1ALDH1A1TSHRHPGDCYP3A4 | |
| SCHEMBL1770014 | 0.69 | HSD11B1 (1.00) | HSD11B1ALDH1A1NPSR1 | |
| SCHEMBL3323351 | 0.69 | NPC1 (0.51) | HSD11B1ALDH1A1NPSR1TSHRHPGD | |
| SCHEMBL1770271 | 0.68 | HSD11B1 (0.52) | HSD11B1ALDH1A1NPSR1TSHRHPGD | |
| SCHEMBL3321985 | 0.68 | ALDH1A1 (0.65) | HSD11B1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL1770013 | 0.67 | HSD11B1 (0.50) | HSD11B1ALDH1A1NPSR1CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112151-A1 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
| US-20110112151-A1 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
| US-20110112151-A1 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE | STERIX LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112151-A1 | COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE | HSD11B1, HSD11B2, HSD3B1 | HSD11B1 1/4885ALDH1A1 307/4885NPSR1 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.